This strengthens Google’s position against rivals such as Microsoft and AWS as enterprises seek faster, more reliable ways to deploy and manage AI agents. Google Cloud has updated its Vertex AI Agent ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2025 financial results on Monday, November 3, 2025, after the financial markets close. The ...

Eli Lilly has reached a deal to acquire SiteOne Therapeutics that would give it control of a non-opioid pain drug that would compete with a recently approved therapy from Vertex Pharma. The all-cash ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies together. A trend in gene therapy setbacks continues as Vertex Pharmaceuticals ...

During Florida Institute of Technology President John Nicklow's interview activities leading up to his April 2023 hiring, he toured CAMID, the university's sprawling 100,494-square-foot ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the company’s fifth cystic fibrosis treatment Alyftrek and its non-opioid pain relief ...

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges: variable efficacy vs opioids, generic competition, and entrenched prescriber habits limit near-term potential. Phase 2 ...

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at least as effective and costs only 50 cents a pill? They will if the generic ...

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment. It’s the first new class of pain ...

Jan 30 (Reuters) - The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' (VRTX.O), opens new tab drug to treat acute pain, the health regulator said on Thursday, offering a ...

Vertex Pharmaceuticals stock declined almost 13% in six months due to poor test results for a new drug. When it comes to the drug and biotech sector, a major pipeline setback can hit the stock hard.

Vertex Pharmaceuticals' suzetrigine showed lackluster Phase II results, but I still see potential in the non-addictive pain management market given the opioid crisis. Vertex's dominance in the cystic ...